

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1-2. (Cancelled)

3. (Currently amended) An isolated polypeptide selected from the group consisting of: GYRQRLE (SEQ ID NO:1), EYRYRSV (SEQ ID NO:2), GQRARIS (SEQ ID NO:3) and QARRRQS (SEQ ID NO:4).

4-5. (Cancelled)

6. (Previously presented) An isolated polypeptide having one or more R-X-R sequences, wherein at least one R of an R-X-R sequence has been substituted with another amino acid, and wherein the substituted polypeptide is exported from the ER in an amount or at a rate greater than the unsubstituted polypeptide, and wherein said polypeptide is CFTR.

7-52. (Cancelled)

53. (Currently Amended) A ~~pharmaceuteal~~ formulation comprising an isolated polypeptide selected from the group consisting of GYRQRLE (SEQ ID NO:1), EYRYRSV (SEQ ID NO:2), GQRARIS (SEQ ID NO:3), and QARRRQS (SEQ ID NO:4), wherein said formulation polypeptide is in a pharmaceutically acceptable carrier.